An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B.

Journal of Blood Medicine
Nicoletta Machin, Margaret V Ragni

Abstract

Fitusiran is an RNA interference therapeutic that targets antithrombin (AT) in the liver and interferes with AT translation by binding and degrading messenger RNA-AT, thereby silencing AT gene expression and preventing AT synthesis. In both preclinical and clinical studies, AT knockdown results in dose-dependent AT lowering when fitusiran is given weekly or monthly subcutaneously. In clinical trials, fitusiran dose escalation has resulted in improved thrombin generation and clinical hemostasis as measured by reduction in annualized bleed rate. Unlike currently licensed drugs, this improvement was not only in patients with hemophilia A but in also those with hemophilia B, with or without inhibitors. In dental and surgical procedures, fitusiran also provided perioperative hemostasis in association with AT lowering. Fitusiran is well tolerated, with minor local injection site reactions, but in one subject with severe hemophilia A, the concomitant use of daily high-dose factor VIII, inconsistent with trial guidance to avoid high, repeat doses of clotting factor, was associated with fatal thrombosis, suggesting the need for caution when using hemostatic agents in conjunction with fitusiran. Preclinical in vitro and in silico studies...Continue Reading

Citations

Sep 19, 2019·Indian Journal of Pediatrics·Geetha Puthenveetil, Diane Nugent
Mar 3, 2020·Journal of Thrombosis and Haemostasis : JTH·Flora PeyvandiMichael Spannagl
May 13, 2020·Blood Advances·Peter J Lenting
Aug 14, 2020·Genes·Carlos G Moscoso, Clifford J Steer
Sep 17, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Carmen Escuriola-EttingshausenJohannes Oldenburg
Sep 29, 2020·Thrombosis and Haemostasis·Karen AymonnierMarie Christine Bouton
Nov 30, 2019·Blood·Robert F Sidonio, Karen L Zimowski
Jul 2, 2020·Journal of Clinical Medicine·Karishma DhuriRaman Bahal
Sep 16, 2020·Pharmacological Reviews·Ai-Ming YuMei-Juan Tu
Oct 11, 2020·Pharmaceuticals·Muhammad Imran SajidRakesh Kumar Tiwari
Jan 30, 2021·Biochemical Pharmacology·M May ZhangXiao-Bo Zhong
Feb 13, 2021·Pediatric Blood & Cancer·Yakun ZhaoJordan A Shavit
Oct 30, 2020·Journal of Clinical Medicine·Heike DudaChristine Keipert
Jan 26, 2021·Frontiers in Cardiovascular Medicine·Elsa P BianchiniDelphine Borgel
Oct 17, 2020·American Journal of Hematology·Stacy E CroteauAllison P Wheeler
Mar 21, 2021·Haemophilia : the Official Journal of the World Federation of Hemophilia·Victor Jiménez-YusteSilva Zupančić Šalek
Mar 27, 2021·Expert Opinion on Biological Therapy·Wolfgang Miesbach, Fagr Eladly
Dec 18, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·John S S ButterfieldRadoslaw Kaczmarek
Mar 28, 2021·British Journal of Clinical Pharmacology·Francesca TomeoArmando Magrelli
May 5, 2021·Molecular Pharmaceutics·Muhammad Imran SajidRakesh K Tiwari
May 11, 2021·Frontiers in Medicine·Alina-Andreea ZimtaCiprian Tomuleasa
Jul 25, 2021·International Journal of Molecular Sciences·E Carlos Rodríguez-MerchánAntonio Liras
Jul 30, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Dacai XuJinbao Liu
Jan 5, 2019·Bioconjugate Chemistry·Sebastien BenizriPhilippe Barthélémy
Jan 29, 2020·Bioconjugate Chemistry·Arnab RudraRobert Langer
Jun 7, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard James HollandJames Heyes
Oct 22, 2020·Journal of Cardiothoracic and Vascular Anesthesia·Jenny KwakKenichi A Tanaka

❮ Previous
Next ❯

Methods Mentioned

BETA
tail

Software Mentioned

fitusiran

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.